Expertise in
27
conditions

Dr. Cuixia Tian

Pediatrics
Cincinnati Children's Hospital Medical Center
3333 Burnet Ave, 
Cincinnati, OH 
Expertise in
27
conditions
Cincinnati Children's Hospital Medical Center
3333 Burnet Ave, 
Cincinnati, OH 

Overview

Cuixia Tian is a Pediatrics provider in Cincinnati, Ohio. Dr. Tian is highly rated in 27 conditions, according to our data. Her top areas of expertise are Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Dysferlinopathy, and Paramyotonia Congenita.

Her clinical research consists of co-authoring 54 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Pediatrics

Licenses

Pediatrics in OH

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Health Services
  • EPO
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medical Health
  • HMO
  • PPO
Medical Mutual
  • HMO
  • PPO
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

Cincinnati Children's Hospital Medical Center
3333 Burnet Ave, Cincinnati, OH 45229

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Open-Label Extension of the HOPE-2 Duchenne Muscular Dystrophy Trial
Open-Label Extension of the HOPE-2 Duchenne Muscular Dystrophy Trial
Enrollment Status: Active_not_recruiting
Publish Date: November 03, 2025
Intervention Type: Biological
Study Drug: CAP-1002 Allogeneic Cardiosphere-Derived Cells
Study Phase: Phase 2
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Intravenous Delivery of Allogeneic Cardiosphere-Derived Cells in Subjects With Duchenne Muscular Dystrophy
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Intravenous Delivery of Allogeneic Cardiosphere-Derived Cells in Subjects With Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: May 28, 2025
Intervention Type: Drug, Biological
Study Phase: Phase 2
Trial of Pamrevlumab (FG-3019), a Monoclonal Antibody to Connective Tissue Growth Factor, in Non-Ambulatory Subjects With Duchenne Muscular Dystrophy
Trial of Pamrevlumab (FG-3019), a Monoclonal Antibody to Connective Tissue Growth Factor, in Non-Ambulatory Subjects With Duchenne Muscular Dystrophy
Enrollment Status: Terminated
Publish Date: August 27, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 2
A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)
A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Terminated
Publish Date: August 26, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Subjects With Non-ambulatory Duchenne Muscular Dystrophy (DMD)
A Phase 3, Randomized, Double-Blind Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Subjects With Non-ambulatory Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Terminated
Publish Date: March 12, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy and Open-Label Extension
A Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy and Open-Label Extension
Enrollment Status: Completed
Publish Date: January 18, 2024
Intervention Type: Drug
Study Drug: Ataluren
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Global Phase 3 Study of Edasalonexent in Pediatric Patients With Duchenne Muscular Dystrophy
A Randomized, Double-Blind, Placebo-Controlled, Global Phase 3 Study of Edasalonexent in Pediatric Patients With Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: June 21, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Phase III Double-blind, Randomized, Placebo-Controlled Study Assessing the Efficacy, Safety and Tolerability of Idebenone in Patients With Duchenne Muscular Dystrophy Receiving Glucocorticoid Steroids
A Phase III Double-blind, Randomized, Placebo-Controlled Study Assessing the Efficacy, Safety and Tolerability of Idebenone in Patients With Duchenne Muscular Dystrophy Receiving Glucocorticoid Steroids
Enrollment Status: Terminated
Publish Date: December 03, 2021
Intervention Type: Drug
Study Drug: Idebenone
Study Phase: Phase 3
A Phase III Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Idebenone in Patients With Duchenne Muscular Dystrophy (DMD) Who Completed the SIDEROS Study
A Phase III Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Idebenone in Patients With Duchenne Muscular Dystrophy (DMD) Who Completed the SIDEROS Study
Enrollment Status: Terminated
Publish Date: December 03, 2021
Intervention Type: Drug
Study Drug: Idebenone
Study Phase: Phase 3
An Open-Label, Multi-Center, Study With a Concurrent Untreated Control Arm to Evaluate the Efficacy and Safety of Eteplirsen in Duchenne Muscular Dystrophy
An Open-Label, Multi-Center, Study With a Concurrent Untreated Control Arm to Evaluate the Efficacy and Safety of Eteplirsen in Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: January 25, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Ataluren (PTC124®) in Patients Aged ≥2 to <5 Years Old With Nonsense Mutation Dystrophinopathy
A Phase 2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Ataluren (PTC124®) in Patients Aged ≥2 to <5 Years Old With Nonsense Mutation Dystrophinopathy
Enrollment Status: Completed
Publish Date: August 28, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 10 Less Clinical Trials

54 Total Publications

Reclassification of intragenic DMD gene duplications by optical genome mapping resolves uncertainty and improves clinical management.
Reclassification of intragenic DMD gene duplications by optical genome mapping resolves uncertainty and improves clinical management.
Journal: Neuromuscular disorders : NMD
Published: October 13, 2025
Similar Doctors
Expertise in
15
conditions
Dr. Rebecca Marsh
Pediatrics
Expertise in
15
conditions
Dr. Rebecca Marsh
Pediatrics

Cincinnati Children's Hospital Medical Center

3333 Burnet Ave, 
Cincinnati, OH 
 (0.1 miles away)
513-636-4266
Languages Spoken:
English
See accepted insurances

Rebecca Marsh is a Pediatrics provider in Cincinnati, Ohio. Dr. Marsh is highly rated in 15 conditions, according to our data. Her top areas of expertise are Hemophagocytic Lymphohistiocytosis, Non-Langerhans-Cell Histiocytosis, Histiocytosis, Reticulohistiocytoma, and Bone Marrow Transplant.

Expertise in
56
conditions
Dr. Donald Gilbert
Pediatrics
Expertise in
56
conditions
Dr. Donald Gilbert
Pediatrics

Cincinnati Children's Hospital Medical Center

3333 Burnet Ave, 
Cincinnati, OH 
 (0.1 miles away)
513-636-4222
Languages Spoken:
English
See accepted insurances

Donald Gilbert is a Pediatrics provider in Cincinnati, Ohio. Dr. Gilbert is highly rated in 56 conditions, according to our data. His top areas of expertise are Tourette Syndrome, Transient Tic Disorder, Drug Induced Dyskinesia, Chorea, and Deep Brain Stimulation.

Expertise in
159
conditions
Dr. David Neal
Pediatrics
Expertise in
159
conditions
Dr. David Neal
Pediatrics

Office

9560 Children Dr Ste A, 
Mason, OH 
 (17.6 miles away)
513-636-6800
Languages Spoken:
English
See accepted insurances
Offers Telehealth

David Neal is a Pediatrics provider in Mason, Ohio. Dr. Neal is highly rated in 159 conditions, according to our data. His top areas of expertise are Tuberous Sclerosis, Tuberous Sclerosis Complex, Cortical Dysplasia, and Seizures.

Frequently Asked Questions about Dr. Cuixia Tian

How do I make an appointment with Dr. Cuixia Tian?

You can book an appointment with Dr. Cuixia Tian by calling their office at 513-636-4222. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Cuixia Tian a top-rated expert for Duchenne Muscular Dystrophy?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Cuixia Tian is classified as an Elite expert for Duchenne Muscular Dystrophy, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Cuixia Tian specialize in?

While Dr. Cuixia Tian is a Pediatrics, they have specific expertise in Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, and Dysferlinopathy. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Pediatrics.

Does Dr. Cuixia Tian participate in research or clinical trials?

Yes. Dr. Cuixia Tian has published 54 articles and abstracts on conditions like Duchenne Muscular Dystrophy. You can view a list of Dr. Cuixia Tian's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Cuixia Tian accept my insurance?

Dr. Cuixia Tian accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 513-636-4222 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Tian's expertise for a condition
ConditionClose
View All 24 Advanced Conditions
View All 162 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile